An indol-3-yl carboxylic acid in which the carboxylic acid specified is acetic acid.
ChEBI ID: 24803
Member | Definition | Role |
---|---|---|
2-[1-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]-3-indolyl]acetic acid methyl ester | 2-[1-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]-3-indolyl]acetic acid methyl ester | |
2-Methylindole-3-acetic acid | 2-Methylindole-3-acetic acid | |
2-oxindole-3-acetic acid | A member of the class of oxindoles that is 2-oxindole carrying a carboxymethyl substituent at position 3. | 2-oxindole-3-acetic acid |
5-methoxy-methylindoleacetic acid | N-Deschlorobenzoyl indomethacin | |
5-methoxyindoleacetic acid | A member of the class of indole-3-acetic acids in which the hydrogen at position 5 of indole-3-acetic acid has been replaced by a methoxy group. | 5-methoxyindole-3-acetic acid |
cinmethacin | cinmetacin | |
hydroxyindoleacetic acid | A member of the class of indole-3-acetic acids that is indole-3-acetic acid substituted by a hydroxy group at C-5. | (5-hydroxyindol-3-yl)acetic acid |
indole-3-acetic acid ethyl ester | Ethyl 3-indoleacetate | |
indoleacetic acid | A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens has been replaced by a 1H-indol-3-yl group. | indole-3-acetic acid |
indomethacin | A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis. | indometacin |
pai 039 | Tiplasinin |
Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
---|---|---|
pre-1990 | 18,092 (45.98) | 18.7374 |
1990's | 9,295 (23.62) | 18.2507 |
2000's | 6,111 (15.53) | 29.6817 |
2010's | 4,700 (11.95) | 24.3611 |
2020's | 1,147 (2.92) | 2.80 |
Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
---|---|---|
Trials | 2,175 (5.21%) | 5.53% |
Reviews | 1,387 (3.32%) | 6.00% |
Case Studies | 1,571 (3.76%) | 4.05% |
Observational | 17 (0.04%) | 0.25% |
Other | 36,584 (87.66%) | 84.16% |